BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 15838375)

  • 1. Evidence that IL-13R alpha2 chain in human glioma cells is responsible for the antitumor activity mediated by receptor-directed cytotoxin therapy.
    Kawakami K; Kioi M; Liu Q; Kawakami M; Puri RK
    J Immunother; 2005; 28(3):193-202. PubMed ID: 15838375
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interleukin-13 receptor-directed cytotoxin for malignant glioma therapy: from bench to bedside.
    Husain SR; Puri RK
    J Neurooncol; 2003 Oct; 65(1):37-48. PubMed ID: 14649884
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Convection-enhanced delivery of interleukin-13 receptor-directed cytotoxin for malignant glioma therapy.
    Kioi M; Husain SR; Croteau D; Kunwar S; Puri RK
    Technol Cancer Res Treat; 2006 Jun; 5(3):239-50. PubMed ID: 16700620
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular targeting with recombinant cytotoxins of interleukin-13 receptor alpha2-expressing glioma.
    Mintz A; Gibo DM; Madhankumar AB; Debinski W
    J Neurooncol; 2003; 64(1-2):117-23. PubMed ID: 12952292
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Specifically targeted killing of interleukin-13 (IL-13) receptor-expressing breast cancer by IL-13 fusion cytotoxin in animal model of human disease.
    Kawakami K; Kawakami M; Puri RK
    Mol Cancer Ther; 2004 Feb; 3(2):137-47. PubMed ID: 14985454
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Distribution kinetics of targeted cytotoxin in glioma by bolus or convection-enhanced delivery in a murine model.
    Kawakami K; Kawakami M; Kioi M; Husain SR; Puri RK
    J Neurosurg; 2004 Dec; 101(6):1004-11. PubMed ID: 15597761
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gene transfer of interleukin 13 receptor alpha2 chain dramatically enhances the antitumor effect of IL-13 receptor-targeted cytotoxin in human prostate cancer xenografts.
    Kawakami K; Husain SR; Bright RK; Puri RK
    Cancer Gene Ther; 2001 Nov; 8(11):861-8. PubMed ID: 11773976
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interleukin-13 receptor alpha2 chain: a potential biomarker and molecular target for ovarian cancer therapy.
    Kioi M; Kawakami M; Shimamura T; Husain SR; Puri RK
    Cancer; 2006 Sep; 107(6):1407-18. PubMed ID: 16902988
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combined effects of radiation and interleukin-13 receptor-targeted cytotoxin on glioblastoma cell lines.
    Kawakami K; Kawakami M; Liu Q; Puri RK
    Int J Radiat Oncol Biol Phys; 2005 Sep; 63(1):230-7. PubMed ID: 16111594
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interleukin-13 receptor-targeted cancer therapy in an immunodeficient animal model of human head and neck cancer.
    Kawakami K; Kawakami M; Joshi BH; Puri RK
    Cancer Res; 2001 Aug; 61(16):6194-200. PubMed ID: 11507072
    [TBL] [Abstract][Full Text] [Related]  

  • 11. IL-13 receptor-targeted cytotoxin cancer therapy leads to complete eradication of tumors with the aid of phagocytic cells in nude mice model of human cancer.
    Kawakami K; Kawakami M; Puri RK
    J Immunol; 2002 Dec; 169(12):7119-26. PubMed ID: 12471149
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Analysis of target genes induced by IL-13 cytotoxin in human glioblastoma cells.
    Han J; Yang L; Puri RK
    J Neurooncol; 2005 Mar; 72(1):35-46. PubMed ID: 15803373
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Potent antitumor activity of IL-13 cytotoxin in human pancreatic tumors engineered to express IL-13 receptor alpha2 chain in vivo.
    Kawakami K; Kawakami M; Husain SR; Puri RK
    Gene Ther; 2003 Jul; 10(13):1116-28. PubMed ID: 12808442
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cintredekin besudotox in treatment of malignant glioma.
    Mut M; Sherman JH; Shaffrey ME; Schiff D
    Expert Opin Biol Ther; 2008 Jun; 8(6):805-12. PubMed ID: 18476792
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cancer gene therapy utilizing interleukin-13 receptor alpha2 chain.
    Kawakami K
    Curr Gene Ther; 2005 Apr; 5(2):213-23. PubMed ID: 15853729
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adenoviral vector-mediated gene transfer of IL-13Ralpha2 chain followed by IL-13 cytotoxin treatment offers potent targeted therapy for cytotoxin-resistant cancers.
    Saito M; Murata T; Watanabe K; Kawakami K; Suzuki M; Koji T; Puri RK; Kitazato K; Kobayashi N
    Int J Cancer; 2005 Aug; 116(1):1-8. PubMed ID: 15756691
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interleukin-13 receptor as a unique target for anti-glioblastoma therapy.
    Husain SR; Joshi BH; Puri RK
    Int J Cancer; 2001 Apr; 92(2):168-75. PubMed ID: 11291041
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Analysis of interleukin-13 receptor alpha2 expression in human pediatric brain tumors.
    Kawakami M; Kawakami K; Takahashi S; Abe M; Puri RK
    Cancer; 2004 Sep; 101(5):1036-42. PubMed ID: 15329913
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interleukin-13 fusion cytotoxin as a potent targeted agent for AIDS-Kaposi's sarcoma xenograft.
    Husain SR; Puri RK
    Blood; 2000 Jun; 95(11):3506-13. PubMed ID: 10828036
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mutation and functional analysis of IL-13 receptors in human malignant glioma cells.
    Kawakami M; Leland P; Kawakami K; Puri RK
    Oncol Res; 2001; 12(11-12):459-67. PubMed ID: 11939409
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.